• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

处方药物评审:舒芬太尼舌下给药制剂

Formulary Drug Review: Sufentanil Sublingual.

作者信息

Baker Danial E

机构信息

Washington State University, Spokane, USA.

出版信息

Hosp Pharm. 2019 Aug;54(4):222-228. doi: 10.1177/0018578719851726. Epub 2019 May 29.

DOI:10.1177/0018578719851726
PMID:31320770
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6628549/
Abstract

Each month, subscribers to receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of publishes selected reviews in this column. For more information about , contact Wolters Kluwer customer service at 866-397-3433.

摘要

每月,订阅者会收到5至6篇关于新发布或处于3期临床试验后期阶段药物的有充分文献依据的专题论文。这些专题论文面向药学与治疗学委员会。订阅者还会每月收到1页关于对议程以及药房/护理在职培训有用药物的简要专题论文。每月还会提供一份全面的目标药物利用评估/用药评估(DUE/MUE)。订阅后,专题论文可供订阅者在线获取。专题论文可进行定制以满足机构的需求。通过合作,在本专栏发表精选评论。如需了解更多关于……的信息,请致电866 - 397 - 3433联系威科集团客服。

相似文献

1
Formulary Drug Review: Sufentanil Sublingual.处方药物评审:舒芬太尼舌下给药制剂
Hosp Pharm. 2019 Aug;54(4):222-228. doi: 10.1177/0018578719851726. Epub 2019 May 29.
2
Formulary Drug Review: Edaravone.处方药物审查:依达拉奉
Hosp Pharm. 2017 Dec;52(11):732-736. doi: 10.1177/0018578717734877. Epub 2017 Oct 9.
3
Formulary Drug Review: Ocrelizumab.处方药物评审:奥瑞珠单抗
Hosp Pharm. 2017 Oct;52(9):599-606. doi: 10.1177/0018578717731733. Epub 2017 Sep 17.
4
Formulary Drug Review: Betrixaban.处方药物审查:贝曲西班
Hosp Pharm. 2018 Feb;53(1):29-37. doi: 10.1177/0018578717739397. Epub 2017 Nov 6.
5
Angiotensin II.血管紧张素II
Hosp Pharm. 2018 Jul;53(4):230-233. doi: 10.1177/0018578718778224. Epub 2018 May 24.
6
Omadacycline.奥马环素
Hosp Pharm. 2019 Apr;54(2):80-87. doi: 10.1177/0018578718823730. Epub 2019 Jan 22.
7
Sodium Zirconium Cyclosilicate.环硅酸锆钠
Hosp Pharm. 2019 Feb;54(1):12-19. doi: 10.1177/0018578718817470. Epub 2018 Dec 14.
8
Baloxavir Marboxil.巴洛沙韦酯
Hosp Pharm. 2019 Jun;54(3):165-169. doi: 10.1177/0018578719841044. Epub 2019 Apr 1.
9
Zoster Vaccine Recombinant, Adjuvanted.重组带状疱疹疫苗,含佐剂。
Hosp Pharm. 2018 Jun;53(3):136-141. doi: 10.1177/0018578718767103. Epub 2018 Apr 2.
10
Sugammadex.舒更葡糖钠
Hosp Pharm. 2016 Jul;51(7):585-96. doi: 10.1310/hpj5107-585.

引用本文的文献

1
Low-dose sufentanil does not affect tolerance to LBNP-induced central hypovolemia or blood pressure responses during a cold pressor test.小剂量舒芬太尼并不影响机体对 LBNP 诱导的中心性低血容量的耐受性或冷加压试验期间的血压反应。
Am J Physiol Regul Integr Comp Physiol. 2024 Nov 1;327(5):R497-R507. doi: 10.1152/ajpregu.00003.2024. Epub 2024 Aug 19.

本文引用的文献

1
Sublingual sufentanil (Zalviso) patient-controlled analgesia after total knee arthroplasty: a retrospective comparison with oxycodone with or without dexamethasone.全膝关节置换术后舌下含服舒芬太尼(Zalviso)患者自控镇痛:与含或不含地塞米松的羟考酮的回顾性比较。
J Pain Res. 2018 Dec 14;11:3205-3210. doi: 10.2147/JPR.S185197. eCollection 2018.
2
Non-invasive patient-controlled analgesia in the management of acute postoperative pain in the hospital setting.医院环境中急性术后疼痛管理的非侵入性患者自控镇痛。
Curr Med Res Opin. 2018 Jul;34(7):1179-1186. doi: 10.1080/03007995.2018.1462785. Epub 2018 May 9.
3
Sufentanil sublingual tablet 30mcg for moderate-to-severe acute pain in the ED.舒芬太尼舌下片 30μg 用于急诊科中重度急性疼痛。
Am J Emerg Med. 2018 Jun;36(6):954-961. doi: 10.1016/j.ajem.2017.10.058. Epub 2017 Oct 31.
4
Sufentanil Sublingual Tablet 30 mcg for the Management of Pain Following Abdominal Surgery: A Randomized, Placebo-Controlled, Phase-3 Study.用于腹部手术后疼痛管理的30微克舒芬太尼舌下片:一项随机、安慰剂对照的3期研究。
Pain Pract. 2017 Sep;17(7):848-858. doi: 10.1111/papr.12531. Epub 2017 Feb 10.
5
Sublingual Sufentanil: A Review in Acute Postoperative Pain.舌下舒芬太尼:急性术后疼痛的综述。
Drugs. 2016 Apr;76(6):719-29. doi: 10.1007/s40265-016-0571-6.
6
Sufentanil Sublingual Tablet System for the Management of Postoperative Pain after Knee or Hip Arthroplasty: A Randomized, Placebo-controlled Study.舒芬太尼舌下片系统用于膝关节或髋关节置换术后的疼痛管理:一项随机、安慰剂对照研究。
Anesthesiology. 2015 Aug;123(2):434-43. doi: 10.1097/ALN.0000000000000746.
7
Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers.健康志愿者单次及重复给药舒芬太尼舌下片的药代动力学特性。
Clin Ther. 2015 Jan 1;37(1):145-55. doi: 10.1016/j.clinthera.2014.11.001. Epub 2014 Dec 24.
8
Sufentanil sublingual tablet system for the management of postoperative pain following open abdominal surgery: a randomized, placebo-controlled study.用于开放性腹部手术后疼痛管理的舒芬太尼舌下片系统:一项随机、安慰剂对照研究。
Reg Anesth Pain Med. 2015 Jan-Feb;40(1):22-30. doi: 10.1097/AAP.0000000000000152.
9
Sufentanil sublingual tablet system vs. intravenous patient-controlled analgesia with morphine for postoperative pain control: a randomized, active-comparator trial.舒芬太尼舌下片系统与静脉注射吗啡患者自控镇痛用于术后疼痛控制的比较:一项随机、活性对照试验。
Pain Pract. 2014 Nov;14(8):679-88. doi: 10.1111/papr.12238. Epub 2014 Aug 25.
10
Pharmacokinetics of sublingual sufentanil tablets and efficacy and safety in the management of postoperative pain.舌下含服舒芬太尼片剂的药代动力学及其在术后疼痛管理中的疗效和安全性。
Reg Anesth Pain Med. 2013 Mar-Apr;38(2):131-9. doi: 10.1097/AAP.0b013e3182791157.